BTIG cuts Boston Scientific price target to $49 from $56, keeps Buy rating
BTIG keeps its Buy rating on Boston Scientific and cuts the target to $49 from $56, implying 15.5% upside from the October 28 close of $42.43.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
BTIG kept its Buy rating on Boston Scientific shares but lowered its price target from $56 to $49, a 12.5% cut, according to TradingView. The new target implies a 15.5% gain from the October 28 close of $42.43.
The same source lists five analyst notes over the past 30 days: Needham kept Buy with a $48 target, Stifel kept Buy at $55, Truist Securities kept Buy at $51, Barclays initiated coverage at Equal-Weight with a $48 target, and Citigroup kept Neutral at $48. Price targets in that period ranged from $48 to $55.
why it matters
Changes like this show analysts revisiting their expectations for the stock, but a single target cut rarely shifts the broader medical device sector. For investors, the overall pattern of ratings matters more than one revision.
tags
instruments
sources
- BTIG maintains Boston Scientific at Buy, lowers price target to $49 from $56 — TradingView, 29 October 2026 at 11:02 UTC
- BTIG maintains Fortinet at Buy, lowers price target to $186 from $203 — TradingView, 29 October 2026 at 12:26 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗